Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111537 | 1.00 | SLC6A3 (0.40) | SLC6A3SLC6A4SLC6A2MEN1PRCP | |
| SCHEMBL4025513 | 0.82 | HSD11B1 (0.31) | — | |
| SCHEMBL4025524 | 0.82 | HSD11B1 (0.31) | — | |
| SCHEMBL1111568 | 0.72 | — | — | |
| SCHEMBL1111572 | 0.72 | — | — | |
| SCHEMBL2000021 | 0.70 | — | — | |
| SCHEMBL3366060 | 0.70 | — | — | |
| SCHEMBL7956129 | 0.70 | — | — | |
| SCHEMBL5168798 | 0.70 | — | — | |
| SCHEMBL3366057 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193373-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193373-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7960378-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960378-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2279169-A2 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100063303-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063303-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090239930-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239930-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009117467-A2 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008073752-A2 | CYCLOBUTYL DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239930-A1 | THERAPEUTIC COMPOUNDS | GBA1, ACER2, SLC10A1 | SLC6A3 294/4885SLC6A4 329/4885SLC6A2 159/4885 |
| US-20100063303-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ABCB1 | SLC6A3 1889/4885SLC6A4 1691/4885SLC6A2 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.